Litigation Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-06-19 |
| Court | District Court, D. Delaware | Date Terminated | 2020-04-20 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | BELCHER PHARMACEUTICALS, LLC | ||
| Patents | 10,017,775; 9,283,197 | ||
| Attorneys | David A. Bilson | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-12-13 | 118 | Notice of Service | 's Invalidity Contentions Regarding U.S. Patent No. 9,283,197 filed by Hospira, Inc..(Haney, Megan) (Entered…2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-01-06 | 123 | Transcript | Pharmaceuticals LLC v Hospira Inc., Civil Action No. 10 17-775-LPS. And we set this time to talk about …that he is a manager of patent litigation, patent 3 enforcement, patent prosecution, a whole number…to manage 3 Hospira's portfolio of patent litigation. He supervises and 4 …. He is not involved with 22 the patent prosecution. 23 And on these…Belcher has 15 with third parties about the patent. 16 Communications with the | External link to document |
| 2020-03-31 | 244 | Opinion | bioequivalent product infringes U.S. Patent No. 9,283,197 (“the ’197 Patent”) under the doctrine of equivalents…that it does not infringe the ’197 Patent and, further, that the Patent is invalid and/or unenforceable… infringe the ’197 Patent under the doctrine of equivalents, (2) the ’197 Patent is invalid as obvious…D.I. 201 at ¶¶ 3-5) II. Patent-in-Suit 8. The ’197 Patent, entitled “More Potent and …a named inventor on more than 39 U.S. patents, including patents related to drug development, formulation | External link to document |
| 2020-03-31 | 245 | Order | infringes claims 6 or 7 of U.S. Patent No. 9,283,197 (“the ’197 Patent”). 2. Defendant has…convincing evidence that claims 6 and 7 of the ’197 Patent are invalid for obviousness, that Jugal Taneja …Taneja is an improper inventor, and that the ’197 Patent is unenforceable due to inequitable conduct. Defendants…failed to prove that claims 6 and 7 of the ’197 Patent are invalid due to anticipation. 3. …2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2017-06-16 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,283,197. (ceg) (Entered: 06…2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2018-09-28 | 96 | Memorandum Opinion | x27;s patent, U.S. Patent No. 9,283,197 ('" 197 patent"). 1 (See id. 124) The patent discloses…characterization of its patent as a "pioneer" patent, and its argument that such a patent is entitled …; It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification … appropriate solvent. See ' 197 patent, 3: 15-42. The patent also explains that the active pharmaceutical | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
